Table 3.
Lymphoproliferative disease in HTLV-infected NSG mice
| Spleen | Lymph nodes and thymus | Lung | Liver | Urinary tract and kidney | Reproductive tract | Salivary and adrenal glands | |
| None | 0% (10/10) | 0% (10/10) | 0% (10/10) | 0% (10/10) | 0% (10/10) | 0% (10/10) | 0% (10/10) |
| HTLV1 (MT2) | 75% (6/8) | 60% (3/5) | 90% (9/10) | 75% (6/8) | 80% (4/5) | 100% (5/5) | 80% (4/5) |
| HTLV1 (ACH.2) | 67% (6/9) | 50% (3/6) | 67% (6/9) | 22% (2/9) | 33% (2/6) | 67% (4/6) | 17% (1/6) |
| HTLV2 (729-pH6) | 80% (4/5) | 80% (4/5) | 100% (5/5) | 86% (6/7) | 40% (2/5) | 80% (4/5) | 40% (2/5) |
| HTLV1–Env2 | 50% (3/6) | 14% (1/7) | 33% (2/6) | 0% (0/6) | 0% (0/7) | 14% (1/7) | 14% (1/7) |
| HTLV2–Env1 | 63% (5/8) | 12% (1/8) | 50% (4/8) | 0% (0/8) | 0% (0/8) | 12% (1/8) | 12% (1/8) |
Numbers in parentheses denote the number of affected mice / number of mice examined
Necropsy was performed after euthanasia (see Table 2).
Lymphoproliferative disease was histologically defined as lymphocytic aggregates in at least 2 organs in diseased animals. In addition, MT2-infected mice had lymphocytic aggregates in brain, heart, and pancreas; 6 HUSC-inoculated mice did not exhibit any disease or lymphocytic aggregates.